Lancet 375 , 14471456 (2010)
Mann JFE, Rossing P, Bakris G, Belmar N, Bosch-Traberg H, Busch R, Charytan DM, Hadjadj S, Gillard P, Gorriz JL, et al
Future Perspectives of GLP-1 RA Use in People with T2D People with T2D are at higher risk of CV events compared with those without T2D, and CV disease is the major cause of death in people with T2D [97]
A SGLT2i + DPP4i FDC is a suitable option for Indian T2D patients, for the following reasons: Safer, rapid, and sustained glycemic control Improves both insulin resistance and beta cell function Helps reduce body weight and blood pressure (extraglycemic benefits) Reduces pill burden (adherence and compliance improves) Overall cost effective The following decision-making algorithms (Fig
76(SUPPL 110):52 Ouellette S, Frias G, Shah R, Alamgir M, Wassef C (2023) Dermal hypersensitivity reaction to semaglutide: two case reports